<DOC>
	<DOCNO>NCT02737150</DOCNO>
	<brief_summary>Aim study demonstrate equivalence second-generation self-expandable valve ( CoreValve Evolut R ) comparison second-generation balloon-expandable valve ( Edwards Sapien 3 ) local anesthesia conscious sedation comparison general anesthesia respect safety efficacy high-risk patient severe aortic stenosis undergo transcatheter aortic valve implantation .</brief_summary>
	<brief_title>SecOnd-generation seLf-expandable Versus Balloon-expandable Valves gEneral Versus Local Anesthesia TAVI</brief_title>
	<detailed_description />
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<criteria>Severe symptomatic aortic valve stenosis define aortic valve area ( AVA ) ≤ 1cm2 0.6 cm²/m² Age ≥75 year and/or logistic European System Cardiac Operative Risk Evaluation ( EuroSCORE ) ≥20 % and/or Society Thoracic Surgeons ( STS ) risk score ≥10 % and/or high risk/contraindication conventional surgical aortic valve replacement Native aortic valve annulus measure 1829 mm Suitability transfemoral vascular access Written inform consent Life expectancy &lt; 12 month due comorbidities Cardiogenic shock hemodynamic instability History active endocarditis Contraindications transfemoral access Active peptic ulcer upper gastrointestinal bleeding &lt; 3 month Hypersensitivity contraindication aspirin , heparin clopidogrel Contraindication specific mode anesthesia judge cardiac anesthesia representative Heart Team Active infection require antibiotic treatment Participation another trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>